156 related articles for article (PubMed ID: 32188328)
1. High-Grade Endometrioid Carcinoma of the Endometrium With a GATA-3-Positive/PAX8-Negative Immunophenotype Metastatic to the Breast: A Potential Diagnostic Pitfall.
Salibay C; Fadare O
Int J Surg Pathol; 2020 Sep; 28(6):631-636. PubMed ID: 32188328
[TBL] [Abstract][Full Text] [Related]
2. Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers.
Ramalingam P; Masand RP; Euscher ED; Malpica A
Int J Gynecol Pathol; 2016 Sep; 35(5):410-8. PubMed ID: 26598976
[TBL] [Abstract][Full Text] [Related]
3. p53 aberrations in low grade endometrioid carcinoma of the endometrium with nodal metastases: possible insights on pathogenesis discerned from immunohistochemistry.
Fadare O; Parkash V
Diagn Pathol; 2017 Nov; 12(1):81. PubMed ID: 29137657
[TBL] [Abstract][Full Text] [Related]
4. Dedifferentiation in Breast Metastasis of Endometrial Carcinoma: A Diagnostic Dilemma.
Shah VI; Morgan SE; Köbel M; Lee CH; McCluggage WG
Int J Gynecol Pathol; 2022 Jan; 41(1):35-39. PubMed ID: 33741764
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
6. Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.
Hu S; Hinson JL; Matnani R; Cibull ML; Karabakhtsian RG
Mod Pathol; 2018 Feb; 31(2):358-364. PubMed ID: 28984301
[TBL] [Abstract][Full Text] [Related]
7. High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.
Murali R; Davidson B; Fadare O; Carlson JA; Crum CP; Gilks CB; Irving JA; Malpica A; Matias-Guiu X; McCluggage WG; Mittal K; Oliva E; Parkash V; Rutgers JKL; Staats PN; Stewart CJR; Tornos C; Soslow RA
Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S40-S63. PubMed ID: 30550483
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours.
Hoang LN; Lee YS; Karnezis AN; Tessier-Cloutier B; Almandani N; Coatham M; Gilks CB; Soslow RA; Stewart CJ; Köbel M; Lee CH
Histopathology; 2016 Oct; 69(4):560-9. PubMed ID: 27101785
[TBL] [Abstract][Full Text] [Related]
9. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
10. Defective DNA Mismatch Repair Influences Expression of Endometrial Carcinoma Biomarkers.
Okoye EI; Bruegl AS; Fellman B; Luthra R; Broaddus RR
Int J Gynecol Pathol; 2016 Jan; 35(1):8-15. PubMed ID: 25851713
[TBL] [Abstract][Full Text] [Related]
11. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J
Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases.
Espinosa I; Gallardo A; D'Angelo E; Mozos A; Lerma E; Prat J
Int J Gynecol Pathol; 2015 May; 34(3):257-65. PubMed ID: 25844549
[TBL] [Abstract][Full Text] [Related]
13. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.
Rambau PF; Duggan MA; Ghatage P; Warfa K; Steed H; Perrier R; Kelemen LE; Köbel M
Histopathology; 2016 Aug; 69(2):288-97. PubMed ID: 26799366
[TBL] [Abstract][Full Text] [Related]
14. Expression of neuroendocrine markers in non-neuroendocrine endometrial carcinomas.
Moritz AW; Schlumbrecht MP; Nadji M; Pinto A
Pathology; 2019 Jun; 51(4):369-374. PubMed ID: 31040050
[TBL] [Abstract][Full Text] [Related]
15. GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.
Davis DG; Siddiqui MT; Oprea-Ilies G; Stevens K; Osunkoya AO; Cohen C; Li XB
Hum Pathol; 2016 Jan; 47(1):26-31. PubMed ID: 26527523
[TBL] [Abstract][Full Text] [Related]
16. Mismatch repair protein deficient endometrioid adenocarcinomas, metastasizing to adrenal gland and lymph nodes: Unusual cases with diagnostic implications.
Rekhi B
Indian J Pathol Microbiol; 2015; 58(4):491-5. PubMed ID: 26549074
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K
Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644
[TBL] [Abstract][Full Text] [Related]
18. FIGO Grade 3 Endometrioid Adenocarcinomas With Diffusely Aberrant β-Catenin Expression: An Aggressive Subset Resembling Cutaneous Pilomatrix Carcinomas.
Weisman P; Park KJ; Xu J
Int J Gynecol Pathol; 2022 Mar; 41(2):126-131. PubMed ID: 33811207
[TBL] [Abstract][Full Text] [Related]
19. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression.
Hafez NH; Shaaban HM
Turk Patoloji Derg; 2018; 34(2):143-149. PubMed ID: 29235613
[TBL] [Abstract][Full Text] [Related]
20. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
